Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8330

Drug Profile

AZD 8330

Alternative Names: ARRY-424704; ARRY-704; AZD8330

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma
  • Developer AstraZeneca
  • Class Amides; Aniline compounds; Antineoplastics; Dihydropyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Jul 2019 Array Biopharma has been acquired by Pfizer
  • 30 Jun 2013 Discontinued - Phase-I for Solid tumours in USA and Norway (PO)
  • 31 Mar 2011 AstraZeneca completes its phase I trial for Solid tumours in USA and Norway (NCT00454090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top